<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/21/intra-cellular-therapies-nasdaqitci-shares-up-5-5.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-21T21:20:49+00:00"/>
    <meta property="og:title" content="Intra-Cellular Therapies (NASDAQ:ITCI) Shares Up 5.5%"/>
    <meta property="og:description" content="Intra-Cellular Therapies Inc (NASDAQ:ITCI)’s stock price shot up 5.5% on Thursday . The company traded as high as $9.56 and last traded at $9.48, 1,237,700 shares changed hands during trading. An increase of 77% from the average session volume of 699,104 shares. The stock had previously closed at $8.99. A number of brokerages have weighed […]"/>
  </head>
  <body>
    <article>
      <h1>Intra-Cellular Therapies (NASDAQ:ITCI) Shares Up 5.5%</h1>
      <address><time datetime="2019-11-21T21:20:49+00:00">21 Nov 2019, 21:20</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/intra-cellular-therapies-inc-logo.jpg"/>
      </figure>
      <p>Intra-Cellular Therapies Inc (NASDAQ:ITCI)’s stock price shot up 5.5% on Thursday . The company traded as high as $9.56 and last traded at $9.48, 1,237,700 shares changed hands during trading. An increase of 77% from the average session volume of 699,104 shares. The stock had previously closed at $8.99.</p>
      <p>A number of brokerages have weighed in on ITCI. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=ITCI">ValuEngine</a> lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. JMP Securities set a $21.00 price target on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a report on Tuesday, September 10th. Royal Bank of Canada set a $26.00 price target on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a report on Wednesday, August 7th. Jefferies Financial Group initiated coverage on shares of Intra-Cellular Therapies in a report on Monday, August 12th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, BidaskClub raised shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a report on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $22.64.</p>
      <p>The stock has a market capitalization of $498.45 million, a PE ratio of -3.34 and a beta of 1.18. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.77 and a quick ratio of 7.77. The business’s fifty day moving average price is $8.73 and its 200-day moving average price is $10.31.</p>
      <p>Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.17. On average, analysts expect that Intra-Cellular Therapies Inc will post -2.85 earnings per share for the current fiscal year.</p>
      <p>In other news, Director Christopher D. Alafi purchased 485,000 shares of the stock in a transaction dated Tuesday, September 10th. The shares were purchased at an average cost of $10.26 per share, with a total value of $4,976,100.00. Following the completion of the acquisition, the director now owns 341,223 shares in the company, valued at approximately $3,500,947.98. The transaction was disclosed in a document filed with the SEC, which is available at <a href="https://www.sec.gov/Archives/edgar/data/1299430/000120919119049172/xslF345X03/doc4.xml">this link</a>. Also, EVP Mark Neumann sold 6,774 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $8.25, for a total transaction of $55,885.50. Following the completion of the sale, the executive vice president now directly owns 13,448 shares in the company, valued at $110,946. The disclosure for this sale can be found <a href="https://www.sec.gov/Archives/edgar/data/1567514/000120919119053435/xslF345X03/doc4.xml">here</a>. Corporate insiders own 18.20% of the company’s stock.</p>
      <p>Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. raised its stake in Intra-Cellular Therapies by 2.2% in the second quarter. BlackRock Inc. now owns 3,933,274 shares of the biopharmaceutical company’s stock valued at $51,055,000 after purchasing an additional 84,063 shares in the last quarter. Schroder Investment Management Group raised its stake in Intra-Cellular Therapies by 5.6% in the second quarter. Schroder Investment Management Group now owns 1,430,469 shares of the biopharmaceutical company’s stock valued at $18,567,000 after purchasing an additional 75,757 shares in the last quarter. Nuveen Asset Management LLC purchased a new stake in Intra-Cellular Therapies in the second quarter valued at approximately $8,024,000. First Midwest Bank Trust Division raised its stake in Intra-Cellular Therapies by 69.8% in the second quarter. First Midwest Bank Trust Division now owns 600,236 shares of the biopharmaceutical company’s stock valued at $7,791,000 after purchasing an additional 246,644 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Intra-Cellular Therapies by 1.6% in the second quarter. Northern Trust Corp now owns 560,601 shares of the biopharmaceutical company’s stock valued at $7,277,000 after purchasing an additional 8,564 shares in the last quarter. 67.57% of the stock is currently owned by hedge funds and other institutional investors.</p>
      <p><b>About Intra-Cellular Therapies</b> (<a href="https://www.marketbeat.com/stocks/NASDAQ/ITCI/">NASDAQ:ITCI</a>)</p>
      <p>Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.</p>
      <p>Recommended Story: <a href="https://www.marketbeat.com/financial-terms/what-is-qqq-etf/">What is the QQQ ETF?</a></p>
    </article>
  </body>
</html>